The global chemotherapy-induced nausea and vomiting drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The term chemotherapy-induced nausea and vomiting includes emesis and nausea, which can involve a loss of appetite and result in the decreased oral intake of fluids and calories. Therefore, for the management of such conditions, the demand for chemotherapy-induced nausea and vomiting drugs is likely to grow in the near future. Further, the growing geriatric population along with the rising prevalence of cancer are acting as the pivotal factors responsible for the increased demand for these drugs. 

The global chemotherapy-induced nausea and vomiting drugs market is also driven by extensive R&D along with new FDA approvals. For instance, in April 2021, Caplin Steriles has been granted final approval from the US FDA for its abbreviated new drug application (ANDA) prochlorperazine edisylate injection USP, 10 mg/2 mL (5 mg/mL) vials. Prochlorperazine edisylate injection is a drug that is indicated for the control of severe nausea and vomiting.

Some major key players in the market include Novartis International AG, F. Hoffman La-Roche AG, and Merck & Co., Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in November 2021, Heron Therapeutics, Inc. announced the submission of its New Drug Application (NDA) to the US Food and Drug Administration (FDA) for HTX-019 (aprepitant) injectable emulsion. HTX-019 injectable emulsion is intended to be used for the prevention of postoperative nausea and vomiting (PONV) in adults.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Therapy
• By Drug Type

Regions covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape:  Novartis International AG, F. Hoffman La-Roche AG, and Merck & Co., Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Chemotherapy-Induced Nausea and Vomiting Drugs Market Report by Segment

By Type 

• Acute Emesis
• Delayed Emesis
• Anticipatory Emesis
• Refractory Emesis

By Therapy

• Nk-1 Receptor Antagonist 
• Serotonin Receptor Antagonist 
• Others

By Drug Type

• Branded
• Generics

Global Chemotherapy-Induced Nausea and Vomiting Drugs Market Report by Region

North America       

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa